ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO931

The Effect of SARS-CoV-2 Vaccination in a Hemodialysis Population in the Region of Southern Denmark

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Thuesen, Anne Daugaard, Sygehus Lillebalt Kolding Sygehus, Kolding, Denmark
  • Pedersen, Erik Bo, Odense Universitetshospital, Odense, Syddanmark, Denmark
  • Knudsen, Annie Rosenfeldt, Sygehus Lillebalt Kolding Sygehus, Kolding, Denmark
  • Juul-Sandberg, Rikke, Sygehus Lillebalt Kolding Sygehus, Kolding, Denmark
  • Knudsen, Majbrittt, Sydvestjysk Sygehus, Esbjerg, Syddanmark, Denmark
  • Nilsson, Christine, Odense Universitetshospital, Odense, Syddanmark, Denmark
  • Jensen, Per B., Odense Universitetshospital, Odense, Syddanmark, Denmark
  • Bistrup, Claus, Odense Universitetshospital, Odense, Syddanmark, Denmark
Background

Hemodialysis patients are a high-risk, immunocompromised population. Therefore, it is expected that vaccination against SARS Cov-2 will have a reduced efficacy in these patients, who have a high mortality from SARS-CoV-2 infection.

Methods

Prospective observational study performed on three dialysis facilities in the Region of Southern Denmark (Kolding Hospital, Odense University Hospital and Sydvestjysk Hospital Esbjerg) in the period March 2021 through March 2023. SARS CoV-2 anti-S RBD IgG are measured in blood samples collected one, two, five, seventeen and twenty-three month after the second vaccination and furthermore before and one month after the third vaccination see. Anti-S RBD IgG was determined using the SARS-CoV-2 IgG II Quant assay (Abbott Laboratories). Non-responders are defined with anti-S-RBD IgG < 7.1 BAU/ml. All hemodialysis patients received the mRNA vaccine Comirnaty/Pfizer-BioNTech. We have included 249 hemodialysis patients.

Results

Below one percent of the hemodialysis population were infected with the Wild type and Delta COVID-19 variant. Significantly reduction in the anti-S-RBD level from 4 weeks after the second vaccination (mean = 544 BAU/ml SEM ±82) to 20 weeks after (mean = 102.3 BAU/ml SEM±49.1).There was a significant increase in the anti-S RBD level after the third booster vaccination with a large variation (mean = 2403 BAU/ml SEM ±148.3) compared to four weeks after the second (mean = 544 BAU/ml SEM ±82). The fraction of non-responders were markedly reduced after the third vaccination from 26% to 3%. We will present the latest data on the anti-S-RBD level that we continuously measures until March 2023.

Conclusion

Hemodialysis patients seem to loose humoral immunity rapidly after the initial COVID-vaccinations, but gain a significant rise in anti-S RBD antibody levels after the third vaccination. The fraction of non-responders after 3rd dose decreased to 3%.